A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer (HiSCO-02)
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Patients receive infusional oxaliplatin, bevacizumab, and oral TS-1 every 21 days. Primary outcome(s): Response rate Study Design: Single arm Non-randomized
创建时间：
2011-03-15
